The uses and benefits of this combination therapy are relevant for long-term therapeutic areas for respiratory support. This medication is indicated for two chronic conditions: Chronic Obstructive Pulmonary Disease (COPD), and support for asthma in adults and children aged 5 years and older whose condition involves heightened symptomatic manifestations.

---

Sustained Symptom Management

This medication is applied in addressing the ongoing symptom burden of shortness of breath, chronic cough, and chest tightness that characterize chronic airflow obstruction. It is commonly used when symptoms of inflammatory and irritative states interfere with daily functioning. Its use supports general functional stability and may assist with easing the impact of symptoms that become more disruptive during flare-ups.

“The focus is on supporting stable breathing, helping patients cope more steadily with difficult episodes.”

Quick Fact: Symptom focus for Chronic Wheezing and Persistent Cough

---

Target Patient Groups

Breo Ellipta supports consistent management in the appropriate patient groups, including adults with COPD and pediatric patients (5 years and older) whose condition requires the support of an inhaled corticosteroid and a long-acting bronchodilator. This long-term approach assists with maintaining general functional stability and contributes to easing the overall symptom load.

Breo Ellipta is officially indicated for the long-term, once-daily maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) and for the maintenance treatment of asthma.

Populations for Whom Use is Not Recommended or Prohibited

Classification	Prohibited Population / Restriction	Regulatory Status
Contraindicated	Patients with severe hypersensitivity to milk proteins, fluticasone furoate, vilanterol, or any excipients.	Must Not Use
Acute Use	Relief of acute bronchospasm (not a rescue inhaler).	Not Indicated
Combination Use	Concomitant use with other long-acting beta 2-agonists (LABA).	Prohibited
Disease State	Initiation during rapidly deteriorating or potentially life-threatening episodes of COPD or asthma.	Not Recommended
Asthma Control	Patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids (ICS).	Not Recommended

Age-Related Eligibility

Breo Ellipta is indicated for the treatment of asthma in patients aged 5 years and older. Safety and efficacy have not been established in children younger than 5 years of age. For COPD, use is indicated in adults. No dosage adjustment is required for geriatric patients, or those with hepatic or renal impairment.

The official regulatory profile for Breo Ellipta (fluticasone furoate/vilanterol) identifies specific drug classes and substances that necessitate caution or are formally prohibited for co-administration.

Contraindicated Combinations

Co-administration with other Long-Acting Beta2-Agonists (LABAs) is explicitly prohibited in regulatory labeling due to the risk of overdose on the beta2-adrenergic component. The antibiotic Lefamulin is also prohibited because it is a strong CYP3A4 inhibitor, which significantly increases the systemic exposure of the active ingredients.

Pharmacokinetic and Pharmacodynamic Interactions

The two components are metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir) is documented to increase the systemic plasma concentration of both fluticasone furoate and vilanterol. This is a pharmacokinetic interaction that raises the risk for systemic effects.

Pharmacodynamic interactions include: Beta-Blockers may oppose the bronchodilatory effects of vilanterol. Non-Potassium-Sparing Diuretics may potentiate hypokalemia (low potassium) associated with beta2-agonists. Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate the effect of vilanterol on the vascular system.

Population and Food Notes

The systemic exposure of the fluticasone furoate component is increased in patients with moderate or severe hepatic impairment, which is a documented population-specific interaction consideration. Grapefruit juice is noted for its potential to interact due to its inhibition of the CYP3A4 enzyme.

Breo Ellipta comprises fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist. These compounds act locally within the pulmonary tissue via distinct molecular pathways.

Vilanterol is a selective partial agonist at the beta2-adrenoceptor, a G-protein coupled receptor. Activation of this receptor on airway smooth muscle cells stimulates the intracellular enzyme adenylyl cyclase, which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). The resulting increase in intracellular cAMP concentration drives the activation of Protein Kinase A, leading to a phosphorylation cascade that modulates cellular calcium handling, resulting in relaxation of the bronchial smooth muscle.

Fluticasone furoate functions as a glucocorticoid receptor (GR) agonist. Upon binding, the activated GR translocates to the nucleus, where it acts as a transcription factor. This action primarily involves gene repression by inhibiting pro-inflammatory transcription factors, such as NF-kappaB. Simultaneously, it promotes the transcription of anti-inflammatory genes, leading to systemic physiological modulation that includes suppression of inflammatory cell infiltration and mediator release within the airways.

General Principles of Administration

Breo Ellipta is approved for use only by oral inhalation as a dry powder, delivered through the Ellipta device. This medicine is designated strictly for long-term maintenance treatment and must be administered once daily. It is essential that the dose is taken at approximately the same time every day, and under no circumstances should more than one inhalation be taken within a 24-hour period.

Official Dosing Regimens

The standard strength and maximum recommended dosage are specific to the condition being managed. For the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD), the approved dose is one inhalation of 100/25 mcg once daily. For asthma, adults and adolescents may start with 100/25 mcg, with the dose potentially being increased to a maximum of 200/25 mcg once daily if control is inadequate. A lower strength of 50/25 mcg once daily is approved for pediatric patients aged 5 to 11 years with asthma.

Administration Context and Special Rules

This medication is not intended for the relief of sudden breathing difficulties; a separate rescue inhaler should be used for acute episodes. Once the dose is taken, the patient must rinse the mouth with water and spit it out immediately after inhalation to fulfill the procedural requirements. Dosing generally does not require adjustment for older adults or those with renal impairment. However, for patients with moderate or severe hepatic impairment, the maximum recommended dose is limited to 100/25 mcg once daily.

If a dose is missed, it should be skipped, and the next scheduled dose should be taken at the usual time; doses must not be doubled to make up for a missed one.

Research Evidence: Overview of Studies for Breo Ellipta

The available research base for this medicine is composed primarily of large-scale clinical trials and post-marketing observational studies. The evidence is focused on describing patterns observed in lung function and symptom changes for patients with the two approved chronic respiratory conditions. It is important to remember that study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly.

---

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

Research into the use of this medicine for COPD was studied for the long-term maintenance of airflow obstruction, a condition marked by functional limitations and periods of heightened symptoms. The core evidence stems from Randomized Controlled Trials (RCTs) designed to examine outcomes related to either a placebo or its individual active components used alone.

These studies monitored outcomes related to physical discomfort and physiological strain, such as objective lung function measurements (like FEV1). These outcomes were observed in the studies. They also explored episodic changes by tracking the annualized rate of COPD exacerbations (or flare-ups). Findings describe patterns observed in these study populations, with regulatory bodies noting that the evidence base has been assigned a High level for these key outcomes. However, regulatory evidence describes that the clinical metrics studied for the higher dose were not different from the 100/25 mcg dose for the COPD indication.

---

Evidence for use in Asthma

For the asthma indication, research was evaluated in patients whose condition involves periods of heightened symptoms while receiving inhaled corticosteroids (ICS) alone. The research design included double-blind RCTs that often compared the combination to the ICS component alone.

Studies explored outcomes related to systemic or functional imbalance by monitoring asthma control scores reported by patients, alongside changes in lung function measurements. Findings suggest patterns of change in how symptoms evolved in the observed populations during the study periods, and contribute to the broader evidence landscape.

---

Evidence Gaps and Research Uncertainty

While a substantial research base exists, certain aspects remain uncertain or limited. Comparative evidence showing head-to-head performance against all other existing combination therapies is lacking across uniformly designed, long-term studies. Follow-up durations for many active-comparator studies were limited to short or intermediate periods, meaning that definitive comparative data on very long-term outcomes (beyond one year) are not available.

Common questions about Breo Ellipta (FAQ)

Q: What are the most commonly reported side effects when first starting Breo Ellipta?

The most commonly reported effects listed in official product information include infections of the upper airways (like nasopharyngitis and upper respiratory tract infection) and headache. Regulatory data for this medication generally reports common side effects over the full period of use and does not specifically detail differences experienced when first starting treatment.

Q: What happens if you stop using Breo Ellipta suddenly?

Regulatory guidance notes that stopping this medicine abruptly or changing the dosage should be discussed with a healthcare provider. The drug is classified as a maintenance medicine, and discontinuation may be associated with a worsening of chronic respiratory symptoms.

Q: How quickly does Breo Ellipta start to work after the first dose?

This medicine is classified for long-term maintenance and is designed to provide sustained control over 24 hours. Because it is a controller medication, it is not indicated for the relief of sudden breathing problems. A separate rescue inhaler is used for acute episodes of breathlessness, as described in administration context documents.

Q: What is the purpose of the Ellipta inhaler device itself?

The Ellipta is a proprietary dry powder inhaler (DPI) device that is designed to deliver the medicine precisely into the lungs. This device includes an integrated dose counter, which is included to assist in tracking the number of inhalations remaining.

Q: Is a sore throat a common side effect of Breo Ellipta?

Official adverse reaction data indicates that effects such as a sore throat are commonly reported. The regulatory documentation lists both pharyngitis and nasopharyngitis, which are medical terms for inflammation of the throat and the nose/throat area.

Q: Can Breo Ellipta interact with over-the-counter pain relievers like ibuprofen?

Official warnings note that caution may be warranted when combining the corticosteroid component of Breo Ellipta with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen. This combination may be associated with an increased risk of gastrointestinal side effects.

Q: Is there a generic version of Breo Ellipta available?

According to FDA records, an authorized generic version of the active ingredients (fluticasone furoate/vilanterol inhalation powder) has been made available by a licensed company.

Q: Why is Breo Ellipta only used once a day?

Breo Ellipta is formulated for once-daily use because both active ingredients, fluticasone furoate and vilanterol, possess pharmacological properties that allow them to work for a full 24 hours. This sustained action supports the single daily dose for maintenance treatment.

Q: Can using Breo Ellipta make you feel jittery or anxious?

The official label lists anxiety in the postmarketing experience section. The beta2-agonist component of the medicine is noted in regulatory information to potentially cause effects such as nervousness.

Q: Can women use Breo Ellipta during pregnancy?

Official information notes that there are insufficient data from studies in pregnant women to establish a clear drug-associated risk. The regulatory framework requires that the decision to use the medicine during pregnancy be based on a careful assessment of the potential benefits compared to any potential risks to the fetus.

Q: Is it okay to use alcohol while being treated with Breo Ellipta?

The official product label does not specifically list a direct interaction warning with alcohol. However, regulatory guidance indicates that caution is advised for underlying health conditions, such as cardiovascular disorders, which may also be affected by alcohol use.

Q: What specific warnings are included in the official labeling for Breo Ellipta?

The official labeling includes specific warnings for serious risks, such as an increased risk of pneumonia in patients with COPD and the possibility of paradoxical bronchospasm (a sudden worsening of breathing). Furthermore, the label notes specific cautions related to systemic corticosteroid effects, including potential adrenal suppression, and hypersensitivity reactions.

Q: Can I use Breo Ellipta if I am lactose intolerant?

Breo Ellipta contains lactose monohydrate as an inactive ingredient. However, the product is only officially contraindicated (prohibited) for patients with a severe hypersensitivity or allergy to milk proteins, not for lactose intolerance.

Q: What are the typical results seen in clinical trials with Breo Ellipta?

Studies summarized in regulatory documents focused on outcomes such as objective lung function measurements (like FEV1) and symptom control. For COPD, evidence describes patterns of improvement in lung function and a reduction in the rate of flare-ups. For asthma, studies showed changes in lung function and in how patients reported their asthma control.

Q: Is Breo Ellipta designed to be taken at a specific time of day?

Official administration instructions describe that the medicine should be taken once daily at approximately the same time every day. The prescribing information for this medicine does not state a preference for the dose to be taken in the morning or the evening.

Q: Does Breo Ellipta have a black box warning from the FDA?

No, Breo Ellipta does not currently carry a Black Box Warning from the FDA. The FDA has removed the Boxed Warning for this drug class regarding the risk of asthma-related death associated with long-acting beta2-agonists when used in combination with an inhaled corticosteroid.

Q: What should I know about switching from another inhaler to Breo Ellipta?

The official label advises that this medication should not be started during rapidly deteriorating respiratory episodes. If a patient is switching from taking an oral corticosteroid (a systemic corticosteroid), the official documentation notes that the steroid dose should be reduced slowly to allow the adrenal function to recover.

Q: Does Breo Ellipta make you tired or cause insomnia?

Official postmarketing data includes reports of insomnia, or disturbed sleep. While tiredness is not listed as a common side effect, a persistent feeling of being tired may be a sign of systemic corticosteroid effects, such as adrenal suppression, which is a serious risk noted in the label.

Q: Are there restrictions on using Breo Ellipta before a surgery?

The official labeling includes warnings about the potential for systemic corticosteroid effects and impaired adrenal function. The regulatory advice is related to stress periods, such as before or after a surgery, which may require medical management if adrenal function is impaired.

Storage and Disposal of Breo Ellipta

BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder) must be handled and stored according to specific regulatory requirements to ensure product stability.

Storage Conditions

Store the unopened inhaler in the original moisture-protective foil tray with the desiccant.

• Temperature: Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F). The product must be protected from freezing, heat, and direct sunlight.
• Child Safety: Keep the medicine out of the sight and reach of children.

Stability and Disposal

The in-use period for the inhaler begins once it is removed from the foil tray. The device must be discarded when 6 weeks (42 days) have passed since opening, or when the dose counter reads “0,” whichever occurs first.

Dispose of unused or expired product by following local government regulations for pharmaceutical waste.